Immunizations and risk of multiple sclerosis: systematic review and meta-analysis
- 1.5k Downloads
The role of vaccinations in risk of developing multiple sclerosis (MS) or in risk of relapse has not been well established. The aim of this study was to estimate the effect of immunizations on risk of developing MS in adults as well as in subsequent risk of relapse. Systematic search for publications in MEDLINE (1966–January 2011), EMBASE (1977–January 2011) and the Cochrane Central Register of Controlled Trials (CENTRAL) (1961–January 2011). Both randomized clinical trials and non-randomized studies addressing the effect of any Center for Diseases Control (CDC) recommended vaccine for children, adults or travelers and BCG on risk of MS or disease relapse were included. Two reviewers independently extracted information from articles selected using a predefined datasheet. No significant change in the risk of developing MS after vaccination was found for BCG (OR 0.96, 95% CI 0.69–1.34), Hepatitis B (OR 1.00, 95% CI 0.74–1.37), Influenza (OR 0.97, 95% CI 0.77–1.23), Measles–Mumps–Rubella (MMR) (OR 1.02, 95% CI 0.64–1.61), Polio (OR 0.87, 95% CI 0.61–1.25) and Typhoid fever (OR 1.05, 95% CI 0.72–1.53). We found decreased risk of developing MS for Diphtheria (OR 0.60, 95% CI 0.40–0.90) and Tetanus (OR 0.68, 95% CI 0.54–0.84). Influenza immunization was also associated with no change in risk of MS relapse (RR 1.24, 95% CI 0.89–1.72). Risk of developing multiple sclerosis remained unchanged after BCG, Hepatitis B, Influenza, MMR, Polio and Typhoid fever immunization, whereas diphtheria and tetanus vaccination may be associated with a decreased risk of MS. Further research is needed for the remaining vaccines.
KeywordsMultiple sclerosis Systematic review Meta-analysis Vaccines
This study was supported by funding from the Raúl Carrea Institute for Neurological Research, FLENI.
Conflict of interest
- 1.WHO (2005) Immunization against diseases of public health importance. World Health Organization (WHO). http://www.who.int/mediacentre/factsheets/fs288/en/index.html. Accessed 25 Aug 2010
- 5.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700PubMedCrossRefGoogle Scholar
- 6.CDC (2010) Immunization schedule. Center for Disease Control and Prevention of the United States of America. http://www.cdc.gov/vaccines/recs/schedules/default.htm. Accessed 22 Aug 2010
- 16.DeStefano F, Verstraeten T, Jackson LA, Okoro CA, Benson P, Black SB, Shinefield HR, Mullooly JP, Likosky W, Chen RT, Vaccine Safety Datalink Research Group NIP, Centers for Disease Control, Prevention (2003) Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 60(4):504–509. doi: 10.1001/archneur.60.4.504 PubMedCrossRefGoogle Scholar
- 19.Hocine MN, Farrington CP, Touzé E, Whitaker HJ, Fourrier A, Moreau T, Tubert-Bitter P (2007) Hepatitis B vaccination and first central nervous system demyelinating events: reanalysis of a case-control study using the self-controlled case series method. Vaccine 25(31):5938–5943. doi: 10.1016/j.vaccine.2007.05.032 PubMedCrossRefGoogle Scholar
- 25.Miller AE, Morgante LA, Buchwald LY, Nutile SM, Coyle PK, Krupp LB, Doscher CA, Lublin FD, Knobler RL, Trantas F, Kelley L, Smith CR, La Rocca N, Lopez S (1997) A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 48(2):312–314PubMedGoogle Scholar
- 32.Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O’Connell D, Oxman AD, Phillips B, Schünemann HJ, Edejer TT-T, Varonen H, Vist GE, Williams JW, Zaza S, Group GW (2004) Grading quality of evidence and strength of recommendations. BMJ 328(7454):1490. doi: 10.1136/bmj.328.7454.1490
- 35.Baranzini SE, Mudge J, van Velkinburgh JC, Khankhanian P, Khrebtukova I, Miller NA, Zhang L, Farmer AD, Bell CJ, Kim RW, May GD, Woodward JE, Caillier SJ, McElroy JP, Gomez R, Pando MJ, Clendenen LE, Ganusova EE, Schilkey FD, Ramaraj T, Khan OA, Huntley JJ, Luo S, Kwok P-Y, Wu TD, Schroth GP, Oksenberg JR, Hauser SL, Kingsmore SF (2010) Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 464(7293):1351–1356. doi: 10.1038/nature08990 PubMedCrossRefGoogle Scholar
- 47.Cabrera-Gómez JA, Echazabal-Santana N, García-González L, Ramos-Cedeño AM, Rodríguez-Roque MO, López-Hernández O, Cabrera-Núñez JA, De González La Nuez J, Téllez L (2002) A severe episode in a patient with recurrent disseminated acute encephalitis due to vaccination against hepatitis B. For or against vaccination? Rev Neurol 34(4):358–363PubMedGoogle Scholar